StreetInsider.com News Articles

Form 8-K Silo Pharma, Inc. For: Feb 20

Mon, 23 Feb 2026 17:01:00 -0500

si-local-file:///var/storage/secattach/20260223/26044360.html

Form 8-K Silo Pharma, Inc. For: Feb 20

Mon, 23 Feb 2026 17:01:00 -0500

si-local-file:///var/storage/secattach/20260223/26044360.html

Silo Pharma authorizes $1 million share buyback program

Mon, 23 Feb 2026 16:15:16 -0500

Silo Pharma Inc. (NASDAQ: SILO) announced that its board of directors has authorized a share repurchase program to acquire up to $1 million of the company's common stock. The biopharmaceutical company may purchase shares on the open market, through privately negotiated transactions, or through other methods in compliance with Securities and Exchange Commission rules and applicable legal requirements.

The company reported 13,318,273 shares of common stock outstanding as of November 13, 2025, according to its quarterly report for the period ended September 30, 2025.

"We believe that the current capital market conditions should allow us to capture additional value for all shareholders

Silo Pharma Announces Share Buyback Program

Mon, 23 Feb 2026 16:15:00 -0500

Sarasota, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that its board of directors has authorized a share repurchase program to acquire up to $1million of the Company's common stock. The Company may purchase common stock on the open market, through privately negotiated transactions, or otherwise, in compliance with the rules of the United States Securities and Exchange Commission and other applicable legal requirements. The Company had 13,318,273 shares of common stock

Silo Pharma Announces Share Buyback Program

Mon, 23 Feb 2026 16:15:00 -0500

Silo Pharma receives patent allowance in Japan for PTSD drug SPC-15

Wed, 18 Feb 2026 08:28:10 -0500

Silo Pharma Inc. (NASDAQ: SILO) announced that the Japan Patent Office issued a Notice of Allowance for a patent application covering SPC-15, an intranasal therapeutic targeting Post-Traumatic Stress Disorder.

The patent application, titled "Compositions and Methods for the Prevention of Stress-Induced Fear, Depression-Like Behavior, and Anxiety-Like Behavior," covers both composition and method claims related to therapeutic approaches designed to prevent or mitigate behavioral responses associated with stress.

A Notice of Allowance indicates that the patent office has completed its examination and determined that the application meets patentability requirements and should be granted shortly.

"The approval of this patent is extremely important to Silo

Silo Pharma Receives Notice of Allowance in Japan for SPC-15, Expanding Global Intellectual Property Portfolio

Wed, 18 Feb 2026 08:28:00 -0500

Patent strengthens protection for novel PTSD drug and advances the Company’s international IP strategy

SARASOTA, FL, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that the Japan Patent Office has issued a Notice of Allowance for a patent application covering its lead asset, SPC-15, a novel intranasal therapeutic targeting Post-Traumatic Stress Disorder (PTSD).

The allowed application, titled “Compositions and Methods for the Prevention of Stress-Induced Fear,

Silo Pharma Receives Notice of Allowance in Japan for SPC-15, Expanding Global Intellectual Property Portfolio

Wed, 18 Feb 2026 08:28:00 -0500

Patent strengthens protection for novel PTSD drug and advances the Company’s international IP strategy

The allowed application, titled “Compositions and Methods for the Prevention of Stress-Induced Fear,

Form SCHEDULE 13G/A Silo Pharma, Inc. Filed by: Anson Funds Management LP

Tue, 17 Feb 2026 10:25:00 -0500

si-local-file:///var/storage/secattach/20260217/26008834.html

Form SCHEDULE 13G/A Silo Pharma, Inc. Filed by: Anson Funds Management LP

Tue, 17 Feb 2026 10:25:00 -0500

si-local-file:///var/storage/secattach/20260217/26008834.html

Form SCHEDULE 13G/A Silo Pharma, Inc. Filed by: INTRACOASTAL CAPITAL, LLC

Fri, 13 Feb 2026 16:49:00 -0500

si-local-file:///var/storage/secattach/20260213/26001501.html

Form SCHEDULE 13G/A Silo Pharma, Inc. Filed by: INTRACOASTAL CAPITAL, LLC

Fri, 13 Feb 2026 16:49:00 -0500

si-local-file:///var/storage/secattach/20260213/26001501.html

Form SCHEDULE 13G/A Silo Pharma, Inc. Filed by: SEG Opportunity Fund, LLC

Fri, 13 Feb 2026 12:27:00 -0500

si-local-file:///var/storage/secattach/20260213/25997932.html

Form SCHEDULE 13G/A Silo Pharma, Inc. Filed by: SEG Opportunity Fund, LLC

Fri, 13 Feb 2026 12:27:00 -0500

si-local-file:///var/storage/secattach/20260213/25997932.html

Silo Pharma signs letter of intent with Allucent for phase 1 studies

Tue, 30 Dec 2025 08:05:13 -0500

Silo Pharma Inc. (NASDAQ: SILO) entered into a non-binding letter of intent with Allucent (US) LLC to provide clinical research services for two planned Phase 1 studies of its SPC-15 nasal spray in healthy subjects.

The studies include an open-label, single ascending dose study and an open-label, multiple ascending dose study. Allucent and Silo plan to negotiate a Master Services Agreement and project-specific Work Order covering clinical operations, pharmacovigilance, data management, biostatistics, clinical pharmacology modeling and simulation, and medical writing.

The letter of intent outlines proposed payment conditions, including an upfront amount for direct service fees and pass-through costs that would be

Silo Pharma Executes Letter of Intent with Allucent to Support Phase 1 Clinical Development of SPC-15

Tue, 30 Dec 2025 08:05:00 -0500

Planned SAD and MAD Studies Mark Key Clinical Inflection Point for Intranasal PTSD and Anxiety

SARASOTA, FL, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a diversified developmental stage biopharmaceutical and cryptocurrency treasury company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced it has entered into a non-binding Letter of Intent (“LOI”) with Allucent (US) LLC (“Allucent”), a global clinical research organization (CRO), to provide clinical research services for two planned Phase 1 studies evaluating its SPC-15 nasal

Silo Pharma Executes Letter of Intent with Allucent to Support Phase 1 Clinical Development of SPC-15

Tue, 30 Dec 2025 08:05:00 -0500

Planned SAD and MAD Studies Mark Key Clinical Inflection Point for Intranasal PTSD and Anxiety

Form 8-K Silo Pharma, Inc. For: Dec 24

Mon, 29 Dec 2025 09:04:00 -0500

si-local-file:///var/storage/secattach/20251229/25782249.html

Form 8-K Silo Pharma, Inc. For: Dec 24

Mon, 29 Dec 2025 09:04:00 -0500

si-local-file:///var/storage/secattach/20251229/25782249.html

Form 4 Silo Pharma, Inc. For: Dec 15 Filed by: Weisblum Eric

Tue, 16 Dec 2025 18:35:00 -0500

si-local-file:///var/storage/secattach/20251216/25748380.html

Form 4 Silo Pharma, Inc. For: Dec 15 Filed by: Weisblum Eric

Tue, 16 Dec 2025 18:35:00 -0500

si-local-file:///var/storage/secattach/20251216/25748380.html

Form EFFECT Silo Pharma, Inc.

Fri, 28 Nov 2025 06:04:00 -0500

si-local-file:///var/storage/secattach/20251128/25673830.html

Form EFFECT Silo Pharma, Inc.

Fri, 28 Nov 2025 06:04:00 -0500

si-local-file:///var/storage/secattach/20251128/25673830.html

Form 424B3 Silo Pharma, Inc.

Wed, 26 Nov 2025 16:16:00 -0500

si-local-file:///var/storage/secattach/20251126/25671051.html

Form 424B3 Silo Pharma, Inc.

Wed, 26 Nov 2025 16:16:00 -0500

si-local-file:///var/storage/secattach/20251126/25671051.html